Experts discuss findings presented at ASH 2022 regarding chronic lymphocytic leukemia, and how they can be applied to clinical practice.
ONCOLOGY® Companion, Volume 37, Supplement 3
Ravi Vij, MD, MBA, and Luciano Costa, MD, face off over myeloma data from ASH 2022.
A panel of experts from Moffitt and Mayo discuss newly published data from the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition.
Anne-Marie Jacob, a patient with multiple myeloma, discusses the treatment of multiple myeloma with bispecifics alongside a panel of experts.
Experts review the most recent data and discuss current strategies for the management of HR+ metastatic breast cancer.
Joshua Richter, MD, discusses the optimal use of selinexor in the treatment of relapsed/refractory multiple myeloma.
An expert panel highlights novel therapeutic approaches for newly diagnosed and relapsed multiple myeloma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Sac-TMT Combo Produces Encouraging Activity in Pretreated Metastatic CRPC
2
Zurletrectinib Generates Responses in Advanced NTRK Fusion Solid Tumors
3
FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars
4
Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome
5
